Research programme: urokinase inhibitors - Celera Genomics
Alternative Names: APC 6782; Urokinase inhibitors research programme - Celera GenomicsLatest Information Update: 09 Jan 2004
At a glance
- Originator Celera Genomics Group
- Class
- Mechanism of Action Angiogenesis inhibitors; Urokinase-type plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Aug 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 04 Dec 2001 Axys Pharmaceuticals has been acquired by Celera Genomics Group
- 03 Nov 1998 Preclinical development for Cancer in USA (Unknown route)